Floatz logo

Linsitinib

Advanced Solid Tumors

Astellas Pharma Global Development, Inc.Small moleculePhase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
59/ 100

Competitive context

1412 Active assets in the Advanced Solid Tumors cohort.

Asset / SponsorPhaseRating
Nabiximols
Jazz Pharmaceuticals
Phase 3BBB
Inno-206
M.D. Anderson Cancer Center
Phase 2BB
Vitamin B6
M.D. Anderson Cancer Center
Phase 4BB
PROPOFOL
Hong Kong Children's Hospital
Phase 4BB
Rivoceranib
Jiangsu HengRui Medicine Co., Ltd.
Phase 4BB

View all 50 →

Same molecule, other indications

Linsitinib is also rated in:

small cell lung carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
prostate adenocarcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
hormone-resistant prostate carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →